Metrics as of 10/17/2026, 07:38 AM (Berlin time), refresh in progress.
Neurocrine Biosciences Stock
Neurocrine Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Kyle W. Gano
- Employees
- 2,500
- Market cap
- $13.8 B
- IPO
- 23/05/1996
Neurocrine Biosciences, Inc. is a healthcare company based in San Diego, US, dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Founded in 1992, the company is listed on the NASDAQ and employs approximately 2,500…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Neurocrine Biosciences stock: price history
1D
-0.9%
1W
-4.7%
1M
-9.2%
6M
+1.8%
YTD
-4.3%
1Y
-1.3%
2Y
+14.7%
5Y
+29.8%
10Y
+221.1%
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~2% weaker price swings than usual
Neurocrine Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Neurocrine Biosciences is a pharmaceutical company focused on the development and commercialization of medications for neurological, endocrine, and psychiatric disorders. The business model is primarily based on the sale of specialized pharmaceuticals, with INGREZZA for the treatment of tardive dyskinesia representing the core commercial product. Additionally, the company markets substances for Parkinson's disease, endometriosis, and uterine fibroids. A significant part of the strategic direction is the clinical advancement of an extensive drug pipeline for indications such as epilepsy, depression, and schizophrenia, as well as the execution of collaborations and licensing agreements with partners.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Takeda Pharmaceutical Company LimitedDescriptionAsk the agents about Neurocrine Biosciences
Analyst assessment of Neurocrine Biosciences
PRICE TARGET LOW
US$165.00
CONSENSUS
US$204.18
MEDIAN
US$210.00
PRICE TARGET HIGH
US$230.00
0
STRONG BUY
32
BUY
5
HOLD
0
SELL
0
STRONG SELL
37
TOTAL · Buy
As of: 16/10/2026
Neurocrine Biosciences stock metrics
P/E
19.25
P/B
3.71
EV/EBITDA
15.1
RETURN ON EQUITY
3.9%
NET MARGIN
15.1%
DEBT/EQUITY
0.11
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.7%
FLOAT SHARES
100,351,121
AVG. DAILY VOLUME (30D)
1,336,887
Insider transactions (SEC)
GORMAN KEVIN CHARLES
Keswani Sanjay Chandru
Keswani Sanjay Chandru
Cooke Julie
Cooke Julie
Institutional holders
Comparable stocks
Frequently asked questions about Neurocrine Biosciences stock
What does Neurocrine Biosciences do?
Neurocrine Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Kyle W. Gano, the company employs around 2,500 people.
The IPO was on 23/05/1996; the stock trades on NASDAQ under the ticker NBIX.
What do analysts say about Neurocrine Biosciences stock?
37 analysts rate the stock, the consensus is Buy (as of 16/10/2026).
The average price target is US$204.18, ranging from US$165.00 to US$230.00, with a median of US$210.00.
This is an external assessment, not a statement by Market Jury.
When does Neurocrine Biosciences report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly -2% stronger than usual.
Does Neurocrine Biosciences pay a dividend?
No, Neurocrine Biosciences currently does not pay a dividend.
Which stocks are comparable to Neurocrine Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Summit Therapeutics and Halozyme Therapeutics.
How can I get Neurocrine Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Neurocrine Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.